Long-term Clinical Experience with HELP-LDL-Apheresis in Combination with HMG-CoA-Reductase Inhibitors for Maximum Treatment of Coronary Heart Disease Associated with Severe Hypercholesterolemia

1989 ◽  
Vol 35 (3) ◽  
pp. 580-582 ◽  
Author(s):  
THOMAS EISENHAUER ◽  
VICTOR W. ARMSTRONG ◽  
PETER SCHUFF-WERNER ◽  
ECKHARD SCHÜTZ ◽  
JOACHIM THIERY ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Experience ◽  
Ldl Apheresis ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

scholarly journals Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

2010 ◽  
Vol 4 ◽  
pp. CMC.S5970 ◽  
Author(s):  
Robert Guthrie
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Disease Treatment ◽  
Hmg Coa Reductase ◽  
Reductase Inhibitors ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase ◽  
Additional Therapy

Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further reducing cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document